Azeliragon-d9
Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon (HY-50682) . Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) [1]. Azeliragon also can cross the blood-brain barrier (BBB) [2].
Product Specifications
Product Name Alternative
TTP488-d9; PF-04494700-d9
UNSPSC
12352005
Target
Amyloid-β; Isotope-Labeled Compounds
Related Pathways
Neuronal Signaling; Others
Field of Research
Endocrinology; Neurological Disease
Smiles
[2H]C([2H])(C([2H])(C([2H])(C([2H])(C1=NC(C2=CC=C(C=C2)OCCCN(CC)CC)=CN1C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)[2H])[2H])[2H])[2H]
Molecular Formula
C32H29D9ClN3O2
Molecular Weight
541.17
References & Citations
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-50682S/
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
LRRC8E CRISPRa sgRNA lentivector (set of three targets)(Human)
Sheep Fructose-1,6-Bisphosphatase Isozyme 2 (FBP2) ELISA Kit